PSYCHIATRIE PRO PRAXI / Psychiatr. praxi. 2024;25(2):62-70 / www.psychiatriepropraxi.cz 70 PŘEHLEDOVÉ ČLÁNKY Toxická psychóza a její klinický význam -5-TR. Praktická příručka s kódy MKN-10 a MKN-11.Hogrefe – Test centrum s.r.o., Praha, 2023 8. 10. revize Mezinárodní klasifikace nemocí, česká verze, platnost od 1. 1. 2023. https://mkn10.uzis.cz/prohlizec/F10-F19 9. Perälä J, Kuoppasalmi K, Pirkola S, et al. Alcohol-induced psychotic disorder and delirium in the general population. Br J Psychiatry. 2010 Sep;197(3):200-6. 10. Jordaan GP, Nel DG, Hewlett RH, et al. Alcohol-induced psychotic disorder: a comparative study on the clinical characteristics of patients with alcohol dependence and schizophrenia. J Stud Alcohol Drugs. 2009 Nov;70(6):870-6. 11. Soyka M. Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia. Acta Psychiatr Scand. 1990 Mar;81(3):255-9. 12. D’Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):413-31. 13. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28. 14. Schoeler T, Ferris J, Winstock AR. Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis. Transl Psychiatry. 2022 Sep 6;12(1):369. 15. Padhi D, Shukla P, Chaudhury S. Sociodemographic and clinical profile of cannabis-induced psychosis: A comparative study. Ind Psychiatry J. 2021 Oct;30(Suppl 1):S132-S139. 16. Núñez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand. 2002 Mar;105(3):173-8. 17. Vergara-Moragues E, Mestre-Pintó JI, Gómez PA, et al. Can symptoms help in differential diagnosis between substance-induced vs independent psychosis in adults with a lifetime diagnosis of cocaine use disorder? Psychiatry Res. 2016 Aug 30;242:94-100. 18. Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol. 1999;23:323–332. 19. Vergara-Moragues E, González-Saiz F, Lozano OM, et al. Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res. 2012 Dec 30;200(2-3):734-41. 20. Roncero C, Comín M, Daigre C, et al. Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients. Psychiatry Res. 2014 May 30;216(3):398-403. 21. Fiorentini A, Cantù F, Crisanti C, et al. Substance-Induced Psychoses: An Updated Literature Review. Front Psychiatry. 2021 Dec 23;12:694863. 22. Arunogiri S, Verdejo-Garcia A, McKetin R, et al. Emotion Recognition and Impulsive Choice in Relation to Methamphetamine Use and Psychosis Symptoms. Front Psychiatry. 2019 Dec 13;10:889. 23. Hides L, Dawe S, McKetin R, et al. Primary and substance-induced psychotic disorders in methamphetamine users. Psychiatry Res. 2015 Mar 30;226(1):91-6. 24. Gan H, Zhao Y, Jiang H, et al. A Research of Methamphetamine Induced Psychosis in 1,430 Individuals With Methamphetamine Use Disorder: Clinical Features and Possible Risk Factors. Front Psychiatry. 2018 Nov 6;9:551. 25. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000 Winter;9(1):28-37. 26. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003 Dec;6(4):347-52. 27. McKetin R, Baker AL, Dawe S, et al. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Res. 2017 May;251:349-354. 28. Voce A, Calabria B, Burns R, et al. A Systematic Review of the Symptom Profile and Course of Methamphetamine- -Associated Psychosis. Subst Use Misuse. 2019;54(4):549-559. 29. Sara G, Burgess P, Malhi GS, et al. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr Res. 2013;147(2-3):216-22. 30. Yui K, Goto K, Ikemoto S, et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry. 1999 Nov;4(6):512-23. 31. Wearne TA, Cornish JL. A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology. Front Psychiatry. 2018 Oct 10;9:491. 32. Kopeček M, Andrashko V. Racemický ketamin v léčbě rezistentní depresivní poruchy. Od výzkumu ke klinické off-label aplikaci. Psychiatrie. 2022; 26(4): 146–155. 33. Kopeček M, Andrashko V. Pokračovací a udržovací léčba rezistentní depresivní poruchy racemickým ketaminem. Přehled studií. Psychiatrie. 2023; 27(4): 168-178. 34. Pereiro C, Pino C, Flórez G, Arrojo M, Becoña E; COPSIAD Group. Psychiatric Comorbidity in Patients from the Addictive Disorders Assistance Units of Galicia: The COPSIAD Study. PLoS One. 2013 Jun 18;8(6):e66451. 35. Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186(2–3):356-361. 36. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab. Brain. Dis. 2014; 29(2): 351–357. 37. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001 Jul 15;50(2):71-83. 38. Green AI, Drake RE, Brunette MF, et al. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007;164(3):402-8. 39. Gicas KM, Parmar PK, Fabiano GF, Mashhadi F. Substance- -induced psychosis and cognitive functioning: A systematic review. Psychiatry Res. 2022;308:114361. 40. Caton CL, Hasin DS, Shrout PE, et al. Stability of early- -phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry. 2007;190:105-11. 41. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, et al. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev. 2010;29(4):456-61. 42. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. Am J Psychiatry. 2018 Apr 1;175(4):343-350. doi: 10.1176/appi.ajp.2017.17020223. Epub 2017 Nov 28. Erratum in: Am J Psychiatry. 2019 Apr 1;176(4):324. 43. Murrie B, Lappin J, Large M, Sara G. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2020 Apr 10;46(3):505-516. 44. Niemi-Pynttäri JA, Sund R, Putkonen H, et al. Substance- -induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013 Jan;74(1):e94-9. 45. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510-5. 46. Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. Am J Psychiatry. 2019;176(9):711-719. 47. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiat (Suppl.) 1997; 154: 1-63. 48. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53. 49. Pompili M, Amador FX, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Clin Psychiatry. 2007; 6: 10. 50. Chai Y, Luo H, Wei Y, et al. Risk of self-harm or suicide associated with specific drug use disorders, 2004-2016: a population-based cohort study. Addiction. 2022;117(7):1940-1949. 51. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28(12):1115-26. 52. Masopust J, Kopeček M., Protopopová D. Stabilizační a udržovací léčba schizofrenie. Doporučené postup psychiatrické péče 2022. https://postupy-pece.psychiatrie.cz/ specialni-psychiatrie/f2-schizofrenie/stabilizacni-udrzovaci-lecba-schizofrenie. 53. Zarrabi H, Khalkhali M, Hamidi A, et al. Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients. BMC Psychiatry. 2016 Feb;16:44. 54. Campbell EC, Caroff SN, Mann SC. Pharmacotherapy for co-occurring schizophrenia and substance use disorder. UpToDate, Waltham, MA, Wolters Klumer Health. 2024 Feb. 55. Medhus S, Mordal J, Holm B, et al. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res. 2013 Mar 30;206(1):17-21. 56. Srisurapanont M, Arunpongpaisal S, Wada K, et al. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):959-64. 57. Shelly J, Uhlmann A, Sinclair H, et al. First-Rank Symptoms in Methamphetamine Psychosis and Schizophrenia. Psychopathology. 2016;49(6):429-435. 58. Wang LJ, Lin SK, Chen YC, et al. Differences in Clinical Features of Methamphetamine Users with Persistent Psychosis and Patients with Schizophrenia. Psychopathology. 2016;49(2):108-15. 59. Sekiguchi Y, Okada T, Okumura Y. Treatment Response Distinguishes Persistent Type of Methamphetamine Psychosis From Schizophrenia Spectrum Disorder Among Inmates at Japanese Medical Prison. Front Psychiatry. 2021 Jul 19;12:629315. 60. Hajebi A, Amini H, Kashani L, Sharifi V. Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders. Early Interv Psychiatry. 2018 Oct;12(5):928-934. 61. Jordaan GP, Emsley R. Alcohol-induced psychotic disorder: a review. Metab Brain Dis. 2014 Jun;29(2):231-43. 62. Rentero D, Arias F, Sánchez-Romero S, et al. Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use. Adicciones. 2021 Mar 31;33(2):95-108. 63. Rubio G, Marín-Lozano J, Ferre F, et al. Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis. Compr Psychiatry. 2012 Nov;53(8):1063-70.
RkJQdWJsaXNoZXIy NDA4Mjc=